Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» multiple sclerosis
multiple sclerosis
Sanofi’s eyes approval after MS therapy slows disease progression by 31%
Clinical Trials Arena
Sun, 09/22/24 - 09:42 pm
Sanofi
tolebrutinib
MS
multiple sclerosis
FDA
Sanofi lifts lid on MS data behind tolebrutinib’s mixed phase 3 scorecard, plans ‘24 approval filings
Fierce Biotech
Fri, 09/20/24 - 10:15 am
Sanofi
tolebrutinib
clinical trials
MS
multiple sclerosis
Teva faces EU fine for disparaging rival multiple sclerosis medicine, sources say
Reuters
Tue, 09/10/24 - 04:22 pm
Teva Pharmaceutical
Europe
MS
multiple sclerosis
generics
Copaxone
antitrust
Sanofi finds a silver lining in mixed MS drug results
BioPharma Dive
Tue, 09/3/24 - 05:50 pm
Sanofi
tolebrutinib
MS
multiple sclerosis
clinical trials
Sanofi's mixed fortunes in MS drug trials has market focus on win
Reuters
Mon, 09/2/24 - 12:11 pm
Sanofi
multiple sclerosis
MS
clinical trials
tolebrutinib
First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1
Biopharma Reporter
Thu, 08/22/24 - 11:15 am
ImmPACT Bio
CAR-T
MS
multiple sclerosis
FDA
clinical trials
A potential MS ‘game changer’ could bring more safety to the table — even against viruses
Pharma Voice
Tue, 08/13/24 - 11:28 am
Immunic
vidofludimus calcium
MS
multiple sclerosis
FDA grants IND clearance for Indapta’s multiple sclerosis treatment trial
Clinical Trials Arena
Wed, 08/7/24 - 11:40 am
Indapta
FDA
multiple sclerosis
MS
clinical trials
IDP-023
Peloton’s Robin Arzón shines light on MS at Genentech-backed panel
Medical Marketing and Media
Fri, 08/2/24 - 11:41 am
Genentech
pharma marketing
MS
multiple sclerosis
Forbion-backed biotech Progentos debuts with $65M for MS drug
BioPharma Dive
Mon, 05/20/24 - 05:50 pm
Progentos
Forbion
MS
multiple sclerosis
funding
Roche touts near-complete suppression of multiple sclerosis relapse for injectable Ocrevus
Fierce Pharma
Wed, 04/17/24 - 11:33 am
Roche
Ocrevus
MS
multiple sclerosis
AAN
Kyverna reports first use of KYV-101 for multiple sclerosis treatment
Clinical Trials Arena
Tue, 04/2/24 - 11:27 am
Kyverna Therapeutics
KYV-101
multiple sclerosis
Neuro and inflammation biotech Contineum Therapeutics sets terms for $150 million IPO
Renaissance Capital
Mon, 04/1/24 - 12:25 pm
IPOs
Contineum Therapeutics
IPF
multiple sclerosis
Viatris' launch plans scuttled as FDA rebuffs long-acting MS drug from partner Mapi
Fierce Pharma
Mon, 03/11/24 - 11:32 am
Viatris
FDA
Mapi Pharma
MS
multiple sclerosis
glatiramer acetate depot
Bristol Myers Squibb reports data from Phase III multiple sclerosis trial
Clinical Trials Arena
Fri, 03/1/24 - 11:39 am
Bristol Myers Squibb
clinical trials
Zeposia
MS
multiple sclerosis
Sanofi shares positive results from trial of frexalimab for MS
Clinical Trials Arena
Fri, 02/16/24 - 11:43 am
Sanofi
clinical trials
MS
multiple sclerosis
frexalimab
Biogen returns ex-U.S. rights of MS drug Fampyra to Acorda
Fierce Pharma
Thu, 01/11/24 - 08:45 pm
Biogen
Fampyra
MS
multiple sclerosis
Acorda Therapeutics
5 FDA Decisions to Watch in Q1
BioSpace
Tue, 01/2/24 - 11:24 am
FDA
Iovance Biotherapeutics
melanoma
lifileucel
Minerva Neurosciences
schizophrenia
roluperidone
Viatris
Mapi Pharma
MS
multiple sclerosis
GA Depot
Madrigal Pharmaceuticals
NASH
resmetirom
Vertex Pharmaceuticals
CRISPR Therapeutics
exa-cel
beta thalassemia
Europe revokes marketing authorization for generic versions of Biogen's MS drug
Reuters
Tue, 12/19/23 - 10:08 am
Biogen
Tecfidera
MS
multiple sclerosis
Europe
generics
Genentech's MS drug on partial hold in US after liver enzyme elevations in 2 patients
Fierce Biotech
Mon, 12/4/23 - 06:14 pm
Genentech
Roche
MS
multiple sclerosis
fenebrutinib
clinical trials
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »